Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients with Relapsed Or Refractory CD19+ Leukemia and Lymphoma. Here, CD19 is linked to leukemia.